CN109620911B - Traditional Chinese medicine composition capable of improving neutropenia after chemotherapy and application thereof - Google Patents
Traditional Chinese medicine composition capable of improving neutropenia after chemotherapy and application thereof Download PDFInfo
- Publication number
- CN109620911B CN109620911B CN201910091633.0A CN201910091633A CN109620911B CN 109620911 B CN109620911 B CN 109620911B CN 201910091633 A CN201910091633 A CN 201910091633A CN 109620911 B CN109620911 B CN 109620911B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- chemotherapy
- neutropenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 112
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 68
- 208000004235 neutropenia Diseases 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 24
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 24
- 235000008434 ginseng Nutrition 0.000 claims abstract description 24
- 241000173529 Aconitum napellus Species 0.000 claims abstract description 19
- 229940023019 aconite Drugs 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 17
- 241000208688 Eucommia Species 0.000 claims abstract description 16
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 15
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 15
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 14
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 14
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 14
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 14
- 241000288784 Barleria cristata Species 0.000 claims abstract 2
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 2
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 12
- 244000248557 Ophiopogon japonicus Species 0.000 claims description 8
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 8
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 229930195210 Ophiopogon Natural products 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 22
- 238000005728 strengthening Methods 0.000 abstract description 7
- 240000000249 Morus alba Species 0.000 abstract description 6
- 235000008708 Morus alba Nutrition 0.000 abstract description 6
- 230000008093 supporting effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 241000208340 Araliaceae Species 0.000 description 22
- 241000736199 Paeonia Species 0.000 description 15
- 210000000440 neutrophil Anatomy 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 241000207929 Scutellaria Species 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 240000006688 Telosma cordata Species 0.000 description 7
- 235000017352 Telosma cordata Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 5
- 235000021286 stilbenes Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 201000010000 Agranulocytosis Diseases 0.000 description 4
- 241001253169 Asystasia gangetica Species 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 206010018687 Granulocytopenia Diseases 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 229940108949 paclitaxel injection Drugs 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 241000227129 Aconitum Species 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000292 leukogenic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003448 neutrophilic effect Effects 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 244000137773 Viola philippica Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for improving neutropenia after chemotherapy and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 20-40 parts of ginseng, 30-50 parts of prepared aconite, 10-20 parts of ganoderma lucidum, 40-60 parts of radix glehniae, 20-40 parts of eucommia bark, 20-40 parts of Chinese herbaceous peony, 20-40 parts of dwarf lilyturf tuber, 15-30 parts of baical skullcap root, 15-30 parts of white mulberry root-bark, 15-30 parts of philippine violet herb and 10-25 parts of honey-fried licorice root, has the effects of tonifying qi and supporting yang, nourishing yin and clearing heat, and strengthening body resistance and consolidating constitution, and can be used for improving neutropenia after chemotherapy. In the traditional Chinese medicine composition provided by the invention, the compatibility of medicines is precise, and the synergistic effect is realized, so that the traditional Chinese medicine decoction prepared by applying the traditional Chinese medicine composition provided by the invention has an obvious effect on improving the neutropenia after chemotherapy, is convenient to apply, has small side effect, and has a wide application prospect.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition and application thereof, in particular to a traditional Chinese medicine composition for improving neutropenia after chemotherapy and application thereof, and belongs to the field of traditional Chinese medicines.
Background
Neutrophils (neutrophiles) are the most common granulocytes, constituting up to 70% of the circulating leukocytes that are primarily resistant to pathogen infection. One group of syndromes that arise due to a decrease in the absolute value of the peripheral blood neutrophils is Neutropenia (Neutropenia), and the risk of a patient developing an infection is closely related to the time to decrease, the rate of decrease, of the neutrophil count. Chemotherapy (Chemotherapy) is one of the conventional methods for treating malignant tumors in modern medicine, and when cancer cells are killed directly, it often damages cells, tissues and organs of the body and affects their physiological functions. Neutropenia (Neutropenia after Chemotherapy) is a common side effect of Chemotherapy, and Neutropenia occurs due to bone marrow suppression after Chemotherapy of most cancer patients, and then resistance is reduced, susceptibility is increased, if serious infection is combined, life is threatened, and execution, clinical effect and survival expectation of a Chemotherapy cycle scheme are affected.
For neutropenia after chemotherapy, granulocyte colony stimulating factor type leukogenic drugs such as rhG-CSF are generally adopted clinically for adjuvant therapy at present, although the rapid leukogenic effect is obvious, the leucogenic drugs are often insufficient in the aspects of stably and continuously leukogenic, synchronously improving clinical symptoms, physical conditions and the like; in addition, the colony stimulating factor can not only cause bone pain, flu-like symptoms, fever, leucocyte reduction after drug withdrawal and other side effects, but also stimulate the growth of certain malignant cells, so that the clinical application of the colony stimulating factor has certain limitation. On the other hand, relevant clinical researches find that before and during chemotherapy, when western medicines have poor leukocyte increasing effect and even severe myelosuppression, the traditional Chinese medicine is applied to prevent and treat granulocytopenia, so that the traditional Chinese medicine clinical symptoms of chemotherapy patients can be improved, a plurality of adverse reactions caused by chemotherapy can be reduced, and the chemotherapy compliance of the patients can be improved. Therefore, the traditional Chinese medicine has unique advantages in improving the neutropenia after chemotherapy.
In traditional Chinese medicine, neutropenia can be classified into "deficiency syndrome", "consumptive disease", "malnutrition" and "blood syndrome", which are related to factors such as deficient innate qi, deficiency of spleen, stomach, liver and kidney, chronic diseases, malnutrition or toxic toxin invasion. Chemotherapy drugs are attached to the exogenous pathogenic factors, and neutrophilic granulocytopenia after chemotherapy is regarded as the sign of "drug toxicity septicemia" in chemotherapy. The toxic and internal invasion of the chemotherapy drugs can easily damage healthy qi, blood vessels, liver and kidney and bone marrow, so that the source of hematopoiesis is inhibited, and the deficiency of primordial qi causes the dysfunction of marrow not producing blood and blood not nourishing marrow. It is worth confirming that, with the theory of traditional Chinese medicine as guidance, following the combination of syndrome differentiation and disease differentiation, traditional Chinese medicine has had great effect in preventing, treating, improving neutropenia after chemotherapy, and improving immunity of the organism, such as relaxation and the like, the related research and analysis are developed aiming at the clinical curative effect of the stilbene gum leucocyte rising capsule on improving neutropenia caused by chemotherapy of non-small cell lung cancer patients, and the result shows that the stilbene gum stilbene leucocyte rising capsule can improve the chemotherapy effect, reduce the incidence rate of neutropenia, the application is safe, the adverse reaction is small, and the stilbene gum leucocyte rising capsule is worthy of clinical popularization (relaxation, tonia, childhood, etc.. the research and analysis of the clinical curative effect of the stilbene leucocyte reducing capsule on improving neutropenia caused by chemotherapy of non-small cell lung cancer patients [ J ]. southeast national defense medicine, 2018, 20 (1): 26-29.); zhang Ping also uses eleven ginseng and astragalus tablets combined with recombinant human granulocyte stimulating factor to treat neutropenia after chemotherapy, obtains better clinical curative effect, can improve the life quality and the body function state of a patient, and has certain clinical popularization and application value (Zhang Ping. curative effect observation of neutropenia after chemotherapy by eleven ginseng and astragalus tablets combined with recombinant human granulocyte stimulating factor [ J ] modern medicine and clinic, 2018, 33 (6): 1472-one 1475.). The traditional Chinese medicine is characterized in that the method is based on the principle, the method is based on the syndrome, the medicines have special characteristics and have combined wonderful functions, so that the formula of the traditional Chinese medicine composition is preferably determined according to the compatibility theory of the monarch, minister, assistant and guide prescription in the traditional Chinese medicine, and the medicines achieve the purposes of precise compatibility, complementary and synergistic effect.
Disclosure of Invention
The traditional Chinese medicine composition comprises ginseng, prepared aconite, ganoderma lucidum, radix glehniae, eucommia, peony, radix ophiopogonis, scutellaria baicalensis, cortex mori radicis, herba violae and honey-fried licorice root, has the effects of tonifying qi and yang, nourishing yin and clearing heat, and supporting the healthy energy, can obviously improve the neutrophilic granulocytopenia after chemotherapy and improve the immunity of the organism, and is used for improving the neutrophilic granulocytopenia after chemotherapy, and the symptoms of mental fatigue and weakness, palpitation and short breath, dizziness, shortness of breath and no talk, lassitude, anorexia, poor appetite, deep and fine pulse and the like. Meanwhile, the traditional Chinese medicine composition for improving the neutropenia after chemotherapy provided by the invention has the advantages of sufficient medicinal material source, low price, simple preparation process and lower treatment cost.
The technical scheme of the invention is as follows:
a traditional Chinese medicine composition for improving neutropenia after chemotherapy comprises the following raw materials in parts by weight:
preferably, the traditional Chinese medicine composition for improving the neutropenia after chemotherapy comprises the following raw materials in parts by weight:
more preferably, the traditional Chinese medicine composition for improving the neutropenia after chemotherapy comprises the following raw materials in parts by weight:
according to the syndrome differentiation theory of traditional Chinese medicine, neutropenia after chemotherapy is more manifested as 'deficiency syndrome', which is called 'deficiency caused by deprivation of essential qi'. In the early stage of the disease, deficiency of both qi and blood and spleen-qi are the main factors, and the liver and kidney are injured for a long time, resulting in deficiency of kidney-yin, kidney-yang or yin-yang, so it is indicated for the treatment of the disease by tonifying qi and supporting yang, nourishing yin to clear heat, and strengthening body resistance to consolidate the constitution. In the formula, ginseng can tonify primordial qi, tonify spleen and lung, consolidate and promote fluid production, soothe nerves and promote intelligence, and is called as "the king of tonics" to treat consumptive disease, deficiency of qi, exhaustion of body fluid and all the syndromes of qi, blood and body fluid deficiency. Modern pharmacological research also shows that ginseng can resist fatigue, aging, shock and cancer, enhance the immune function of the organism, promote the biosynthesis of protein RNA and DNA, regulate the metabolism of cholesterol, promote the function of a hematopoietic system, relieve the damage of radiation to the hematopoietic system and the like. The prepared aconite is a processed product of the Chinese medicinal material aconite, has the effects of strongly tonifying primordial yang, benefiting fire and eliminating yin, enters kidney meridian to supplement true yang, is known as a vital gate main drug, is honest as the theory of ' main drug for the minghan ' of ' medicine, uses the traditional Chinese medicine for meridian running, uses little supplementary drug as a guide and has the effect of strengthening primordial qi and regenerating. The ginseng and the prepared aconite are mutually reinforced, the ginseng can greatly tonify primordial qi, the prepared aconite can tonify fire and strengthen yang, and the ginseng can be directly treated by the prepared aconite without hardness breaking; the monkshood can be successfully completed by the ginseng and the blood vessels are not damaged (Qing & Chen & Wu & Shi' Xin Shu & ao), the two can mutually help, complement each other and have more remarkable effects of tonifying qi and tonifying yang, and the monkshood and the Mongolian monkshood are monarch drugs together.
Ganoderma lucidum is sweet in flavor and neutral in nature, and can tonify heart blood, benefit heart qi and tranquilize mind, so it is a good herb for treating consumptive disease. Modern pharmacological studies show that ganoderma lucidum polysaccharide has wide immunoregulation capability, can improve the immune function of organisms, and can antagonize the low immune function caused by immunosuppressant, antitumor agent, stress and the like to recover or approach to normal. The ganoderma lucidum is compatible with ginseng, and the ganoderma lucidum nourishes qi and blood to help the ginseng to greatly tonify vitality and achieve the purpose of tonifying qi and blood, so the ganoderma lucidum is a ministerial drug. Eucommia bark, cortex Eucommiae, sweet in taste and warm in nature, enters liver and kidney meridians, and can tonify liver and kidney, strengthen tendons and bones, and tonify liver and kidney, which is the key herb (Ming & Ni He Huo & Ben Cao Hui Yan). Modern pharmacological studies also show that the eucommia bark has the functions of enhancing the adrenal cortex of animals, enhancing the immunologic function of organisms and calming. The eucommia bark is combined with the prepared accessory piece, and the eucommia bark accessory piece which is used for tonifying the liver and kidney and assisting the preparation of the accessory piece is used for tonifying fire and supporting yang, and is also used as a ministerial drug for reinforcing the functions of nourishing the liver and the kidney and strengthening the muscles and bones. Bei Sha Shen and Mai Dong are sweet and cold in nature. Bei Sha Shen can tonify lung yin, clear lung heat, nourish stomach and promote fluid production, which is called as "tonify yin to control yang and clear gold to nourish water" from De Cang Ben Cao (de Bo Cao); ophiopogon root, radix Ophiopogonis has the effects of nourishing yin, moistening lung, nourishing stomach yin, nourishing heart yin, clearing away heart heat, so it is called from Jingyue quan Shu that it ascends heart and lung, tonifies body fluids of upper energizer, clears thirst and restlessness of chest and diaphragm, relieves vomiting of inflammation, and relieves asthenic fever of blood dryness; to replenish vital essence and nourish yin. The two are mutually reinforced, so the functions of nourishing yin, clearing heat, benefiting stomach and promoting fluid production are enhanced, and the two are used as ministerial drugs.
Peony root, radix Paeoniae alba, bitter and sour in flavor, slightly cold in nature, is a blood component medicine, can ascend and descend, and can tonify blood, purge liver, benefit spleen, and astringe liver yin, and is called as "liver-inhibiting, middle-jiao-relieving, yang-supporting, yin-nourishing, qi-tonifying and blood-enriching holy medicine" (Ming & Fang Gu "materia Medica of materia Medica); baikal skullcap root, bitter in taste and cold in nature, is mainly used for clearing heat and drying dampness, purging fire and removing toxicity, cooling blood and arresting bleeding, and removing heat and preventing abortion, and can regulate qi, so it can be used for clearing heat due to qi stagnation in any zang-fu organs (Zhang Xi Chun is recorded in Zhong Can xi Lu of medicine). Modern pharmacological studies show that the scutellaria decoction has a wide antibacterial spectrum in vitro and has an inhibitory effect on staphylococcus, streptococcus, pneumococcus, typhoid bacillus, dysentery bacillus and the like. The peony is combined with the scutellaria, and the peony is taken to disperse blood clots and assist the scutellaria to urge to discharge heat of blood clots, and also assist ministerial drugs in nourishing yin and clearing heat. Sang Bai Pi is sweet and cold in nature and special for lung meridian and can purge lung and relieve dyspnea, induce diuresis to alleviate edema, recorded in compendium of materia Medica: it is advisable for the lung to contain water and qi and the rest of lung fire. Viola Yedoensis Makino is bitter and cold in property, enters heart and liver meridians and blood, and has the effects of clearing away heat and toxic materials, eliminating carbuncle and dissipating stagnation. Modern pharmacological studies also show that the Chinese violet has inhibition effects on pneumococcus, staphylococcus aureus, dysentery bacillus, tubercle bacillus and the like, and has antipyretic, detumescence, anti-inflammatory and other effects. The four medicines of the peony root and the like play an assisting role in the treatment of the formula and are used as adjuvant medicines together. Licorice root, radix Glycyrrhizae is a guiding drug because it can regulate the middle warmer, tonify, and harmonize the effects of other drugs in the recipe.
The above 11 medicines such as ginseng, prepared aconite and the like are formulated based on the traditional Chinese medicine clinical syndrome expression of neutropenia after chemotherapy according to the compatibility theory of the monarch, minister, assistant and guide ' prescription in traditional Chinese medicine and following the treatment and regulation concepts of ' strengthening body resistance and consolidating foundation ', ' tonifying yin and yang and supplementing qi ' and ' taking the peaceful period ', and the medicines are combined to play the functions of tonifying qi and strengthening yang, nourishing yin and clearing heat, and strengthening body resistance and consolidating foundation, so that the reduction of neutropenia after chemotherapy can be obviously improved, the immunity of the organism is improved, and the medicine is used for improving the neutropenia after chemotherapy and has each good effect.
The invention also aims to provide a traditional Chinese medicine oral decoction containing the traditional Chinese medicine composition, and the preparation method comprises the following steps:
1) 11 raw materials of ginseng, prepared aconite, red ganoderma lucidum, radix glehniae, eucommia bark, peony, dwarf lilyturf tuber, baical skullcap root, white mulberry root-bark, Chinese violet and honey-fried licorice root are weighed according to the weight part ratio, mixed and filled into a medicine boiling bag and put into a medicine decocting machine, distilled water which is 6 to 10 times of the total weight of the raw materials is added, the power supply is not switched on, and the raw materials are soaked for 30 to 60 minutes.
2) Setting the decocting temperature of the decocting machine to 100 ℃, and setting the decocting time to 2 h; and the power supply is switched on, and the decoction is started.
3) After the medicine is decocted, the power supply is cut off; taking out the residue, filtering the medicinal liquid, packaging, and storing at 4 deg.C.
Detailed Description
The present invention is further illustrated by the following specific examples, but it will be understood by those skilled in the art that the examples are given for illustrative purposes only and do not limit the scope of the present invention in any way.
Example 1A Chinese medicinal composition for improving neutropenia after chemotherapy
The traditional Chinese medicine composition for improving the neutropenia after chemotherapy comprises the following raw materials in parts by weight: 20 parts of ginseng, 30 parts of prepared aconite root, 10 parts of ganoderma lucidum, 40 parts of radix glehniae, 20 parts of eucommia bark, 20 parts of Chinese herbaceous peony, 20 parts of dwarf lilyturf tuber, 15 parts of baical skullcap root, 15 parts of white mulberry root-bark, 15 parts of Chinese violet and 10 parts of honey-fried licorice root.
The dosage form of the traditional Chinese medicine composition for improving the neutropenia after chemotherapy is traditional Chinese medicine oral decoction.
The preparation method of the traditional Chinese medicine composition oral decoction for improving the neutropenia after chemotherapy comprises the following steps:
1) weighing ginseng, prepared aconite, ganoderma lucidum, radix glehniae, eucommia bark, peony, radix ophiopogonis, scutellaria baicalensis, cortex mori radicis, philippine violet herb and honey-fried licorice root according to the weight part ratio, mixing, filling into a medicine boiling bag, putting into a medicine decocting machine, adding distilled water 6 times of the total weight of the medicinal materials, not switching on a power supply, and soaking for 30 min.
2) Setting the decocting temperature of the decocting machine to 100 ℃, and setting the decocting time to 2 h; 2, the power is switched on, and the decoction is started.
3) After the medicine is decocted, the power supply is cut off; taking out the residue, filtering the medicinal liquid, packaging, and storing at 4 deg.C.
Example 2A Chinese medicinal composition for improving neutropenia after chemotherapy
The traditional Chinese medicine composition for improving the neutropenia after chemotherapy comprises the following raw materials in parts by weight: 40 parts of ginseng, 50 parts of prepared aconite root, 20 parts of red ganoderma lucidum, 60 parts of radix glehniae, 40 parts of eucommia bark, 40 parts of Chinese herbaceous peony, 40 parts of dwarf lilyturf tuber, 30 parts of baical skullcap root, 30 parts of white mulberry root-bark, 30 parts of Chinese violet and 25 parts of honey-fried licorice root.
The dosage form of the traditional Chinese medicine composition for improving the neutropenia after chemotherapy is traditional Chinese medicine oral decoction.
The preparation method of the traditional Chinese medicine composition oral decoction for improving the neutropenia after chemotherapy comprises the following steps:
1) weighing ginseng, prepared aconite, red ganoderma, radix glehniae, eucommia bark, peony, ophiopogon root, scutellaria baicalensis, cortex mori radicis, philippine violet herb and honey-fried licorice root according to the weight part ratio, mixing, filling into a medicine boiling bag, putting into a medicine decocting machine, adding distilled water which is 10 times of the total weight of the medicinal materials, not switching on a power supply, and soaking for 60 min.
2) Setting the decocting temperature of the decocting machine to 100 ℃, and setting the decocting time to 2 h; 2, the power is switched on, and the decoction is started.
3) After the medicine is decocted, the power supply is cut off; taking out the residue, filtering the medicinal liquid, packaging, and storing at 4 deg.C.
Example 3A Chinese medicinal composition for improving neutropenia after chemotherapy
The traditional Chinese medicine composition for improving the neutropenia after chemotherapy comprises the following raw materials in parts by weight: 30 parts of ginseng, 40 parts of prepared aconite root, 15 parts of red ganoderma, 50 parts of radix glehniae, 30 parts of eucommia bark, 30 parts of Chinese herbaceous peony, 30 parts of dwarf lilyturf tuber, 20 parts of baical skullcap root, 20 parts of white mulberry root-bark, 20 parts of Chinese violet and 16 parts of honey-fried licorice root.
The dosage form of the traditional Chinese medicine composition for improving the neutropenia after chemotherapy is traditional Chinese medicine oral decoction.
The preparation method of the traditional Chinese medicine composition oral decoction for improving the neutropenia after chemotherapy comprises the following steps:
1) weighing ginseng, prepared aconite, ganoderma lucidum, radix glehniae, eucommia bark, peony, radix ophiopogonis, scutellaria baicalensis, cortex mori radicis, philippine violet herb and honey-fried licorice root according to the weight part ratio, mixing, filling into a medicine boiling bag, putting into a medicine decocting machine, adding distilled water with the weight 8 times of the total weight of the medicinal materials, not switching on a power supply, and soaking for 45 min.
2) Setting the decocting temperature of the decocting machine to 100 ℃, and setting the decocting time to 2 h; 2, the power is switched on, and the decoction is started.
3) After the medicine is decocted, the power supply is cut off; taking out the residue, filtering the medicinal liquid, packaging, and storing at 4 deg.C.
Example 4A Chinese medicinal composition for improving neutropenia after chemotherapy
The traditional Chinese medicine composition for improving the neutropenia after chemotherapy comprises the following raw materials in parts by weight: 35 parts of ginseng, 45 parts of prepared aconite root, 12 parts of red ganoderma, 45 parts of radix glehniae, 20 parts of eucommia bark, 20 parts of Chinese herbaceous peony, 40 parts of dwarf lilyturf tuber, 30 parts of baical skullcap root, 15 parts of white mulberry root-bark, 15 parts of Chinese violet and 20 parts of honey-fried licorice root.
The dosage form of the traditional Chinese medicine composition for improving the neutropenia after chemotherapy is traditional Chinese medicine oral decoction.
The preparation method of the traditional Chinese medicine composition oral decoction for improving the neutropenia after chemotherapy comprises the following steps:
1) weighing ginseng, prepared aconite, ganoderma lucidum, radix glehniae, eucommia bark, peony, radix ophiopogonis, scutellaria baicalensis, cortex mori radicis, philippine violet herb and honey-fried licorice root according to the weight part ratio, mixing, filling into a medicine boiling bag, putting into a medicine decocting machine, adding distilled water which is 10 times of the total weight of the medicinal materials, not switching on a power supply, and soaking for 30 min.
2) Setting the decocting temperature of the decocting machine to 100 ℃, and setting the decocting time to 2 h; 2, the power is switched on, and the decoction is started.
3) After the medicine is decocted, the power supply is cut off; taking out the residue, filtering the medicinal liquid, packaging, and storing at 4 deg.C.
Comparative example 1 an incomplete Chinese medicinal composition for ameliorating neutropenia after chemotherapy
The incomplete traditional Chinese medicine composition for improving the neutropenia after chemotherapy comprises the following raw materials in parts by weight: 20 parts of ginseng, 30 parts of prepared aconite, 10 parts of ganoderma lucidum, 40 parts of radix glehniae and 20 parts of radix ophiopogonis.
The dosage form of the incomplete traditional Chinese medicine composition for improving the neutropenia after chemotherapy is traditional Chinese medicine oral decoction.
The preparation method of the incomplete traditional Chinese medicine composition oral decoction for improving the neutropenia after chemotherapy is similar to that in example 1.
Comparative example 2 an incomplete Chinese medicinal composition for improving neutropenia after chemotherapy
The incomplete traditional Chinese medicine composition for improving the neutropenia after chemotherapy comprises the following raw materials in parts by weight:
15 parts of scutellaria baicalensis, 15 parts of cortex mori radicis, 15 parts of Chinese violet, 20 parts of eucommia ulmoides, 20 parts of Chinese herbaceous peony and 10 parts of honey-fried licorice root.
The dosage form of the incomplete traditional Chinese medicine composition for improving the neutropenia after chemotherapy is traditional Chinese medicine oral decoction.
The preparation method of the incomplete traditional Chinese medicine composition oral decoction for improving the neutropenia after chemotherapy is similar to that in example 1.
In order to verify the effect of the traditional Chinese medicine composition on improving neutropenia after chemotherapy, the inventor carries out animal experiments and typical case research. It should be noted that the drugs selected for the animal experiments and typical case studies of the present invention are the representative formulations and the preparations thereof, and the other formulations and preparations thereof involved in the present invention relate to the experiments and the results thereof, which are not intended to be exhaustive due to space limitations.
Experimental example 1 animal experiments
1 Material
1.1 Experimental animals 80 cynomolgus monkeys of 3-5 years old, half male and female, body weight 3.0-5.0kg, provided by Guangdong island Biotechnology Co., Ltd, license number: SCXK (Yue) 2014-. The animals are raised in special laboratories in cages with the specification of 90 multiplied by 70 cm; the temperature is 22-24 ℃, the relative humidity is 40-60%, the noise is less than or equal to 60dB, the ventilation frequency is 10 times/h, and the natural illumination is carried out; the complete granulated feed for monkeys is used for feeding fruits regularly, and drinking water is boiled and sterilized.
1.2 instruments, reagents and drugs AU480 model full-automatic biochemical analyzer, Beckman Coulter, USA; PE-6800VET model full-automatic animal blood cell analyzer, Shenzhen Shanpu kang electronic Limited; paclitaxel injection (national Standard H20058719) is provided by Yangziang pharmaceutical industry group, Inc. and is used for establishing animal models; the tested drugs were oral decoctions of the Chinese medicinal compositions prepared according to examples 1, 2, 3 and 4 and comparative examples 1 and 2.
2 method
2.1 grouping and modeling 80 cynomolgus monkeys were randomly divided into 8 groups, i.e., a normal control group, a model control group, an example 1 group, an example 2 group, an example 3 group, an example 4 group, a comparative example 1 group, and a comparative example 2 group, each of which was 10, according to male and female halves. Taking a paclitaxel injection, and diluting the paclitaxel injection with normal saline until the concentration is 1.2mg/mL for later use; except for the normal control group, 7 groups of paclitaxel injection after intravenous drip dilution are respectively used for constructing a cynomolgus monkey model simulating neutropenia after clinical chemotherapy. And (4) venous blood collection, wherein biochemical and conventional blood indexes of the animal blood of the model are detected, and the success of modeling is determined.
2.2 administration after successful modeling, the gavage administration is started, 2 times a day, 100mL each time, and 7 days are 1 course of treatment. Wherein the normal control group and the model control group are given drinking water sterilized by boiling in the same volume; the example 1 group, the example 2 group, the example 3 group, the example 4 group, the comparative example 1 group and the comparative example 2 group were administered with the respective test drugs.
2.3 index detection venous blood of animals in each test group is collected respectively before administration (Day0) and 24h after administration (Day7) after successful modeling, the blood sample amount is 2mL, EDTA-K is used2Performing anticoagulation treatment; and (3) detecting the percentage of the neutrophils and the absolute value of the neutrophils in each test group by adopting a PE-6800VET type full-automatic animal blood cell analyzer.
2.4 statistical processing analysis was performed using SPSS16.0 statistical software. Experimental data are expressed as mean ± sd
Formally, comparison of differences between groups was performed using one-way anova. P < 0.05 indicates that the difference is statistically significant.
3 results
After 7 days of administration, the change of the percentage of neutrophils and the absolute number of neutrophils in each test group can be observed by detecting the blood routine. The analysis results are shown in tables 1 and 2:
TABLE 1 percentage change of neutrophils in animals of each test group (1)
％)
Note: comparison with normal control group: # P < 0.01; comparison with model control group: p < 0.01; comparison with example 1 group: p < 0.01.
TABLE 2 Absolute Change in neutrophil value in animals of each test group ((
109·L-1)
Note: comparison with normal control group: # P < 0.01; comparison with model control group: p < 0.01; comparison with example 1 group: p < 0.01.
As is clear from tables 1 and 2, the test drugs for the groups of example 1, example 2, example 3 and example 4 all improved the neutropenia in venous blood of the cynomolgus monkey model with neutropenia after chemotherapy, were significantly different from the model control group, and the best example of the present invention was found to be the group of example 3, which had the best improvement effect. Meanwhile, experimental data of the comparative example group and the comparative example group show that the traditional Chinese medicine composition for improving the neutropenia after chemotherapy provided by the invention is scientific and reasonable in formula and component proportion, obvious in synergistic effect and capable of remarkably improving the neutropenia after chemotherapy.
Experimental example 2 typical case study
Case 1: a patient is Zhang-a, male, and 64 years old, the lung cancer is diagnosed, and after the patient receives the gemcitabine and cisplatin chemotherapy scheme in a hospital for 1 week, the symptoms of mental fatigue, hypodynamia, dizziness, palpitation, insomnia, inappetence and deep and thready pulse appear. The indexes such as neutrophils and the like are obviously reduced (the absolute value of the neutrophils is 1.16 multiplied by 10^9/L) in the conventional detection of blood. After the oral traditional Chinese medicine decoction prepared in the embodiment 3 of the invention is taken for 4 weeks, 1 time in the morning and at night and 200mL each time, each index of the routine blood detection basically returns to normal (the absolute value of the neutrophil is 3.79 multiplied by 10^9/L), and can be maintained to be stable.
Case 2: patients were Song in, female, 51 years old, confirmed to be ovarian cancer, treated in the hospital for 2 weeks on a "paclitaxel + carboplatin" chemotherapy regimen, and blood was routinely tested: the absolute value of the neutrophil is 1.22 x 10^ 9/L. Patients complain of the recent symptoms of lassitude, palpitation, shortness of breath, insomnia, anorexia, sallow complexion, white and greasy tongue coating, and thready and weak pulse. After the oral traditional Chinese medicine decoction prepared in the embodiment 3 of the invention is taken for 4 weeks, 1 time in the morning and at night and 200mL each time, each index of the blood routine test basically returns to normal (the absolute value of the neutrophil is 4.03 multiplied by 10^ 9/L). No obvious discomfort reaction occurs during the taking period.
Claims (6)
1. A traditional Chinese medicine composition for improving neutropenia after chemotherapy is characterized by comprising the following raw materials in parts by weight:
2. the traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight:
3. the traditional Chinese medicine composition according to claim 2, which is prepared from the following raw materials in parts by weight:
4. the pharmaceutical composition according to any one of claims 1 to 3, for the preparation of a medicament for ameliorating neutropenia after chemotherapy.
5. A Chinese medicinal oral decoction, which comprises the Chinese medicinal composition as claimed in any one of claims 1 to 3.
6. The traditional Chinese medicine oral decoction according to claim 5, which is prepared by the following steps:
1) weighing 11 raw materials of ginseng, prepared aconite, ganoderma lucidum, radix glehniae, eucommia bark, peony, ophiopogon root, scutellaria baicalensis, cortex mori radicis, philippine violet herb and honey-fried licorice root according to the weight part ratio, mixing, filling into a medicine boiling bag, putting into a medicine decocting machine, adding distilled water 6-10 times of the total weight of the raw materials, not switching on a power supply, and soaking for 30-60 min;
2) setting the decocting temperature of the decocting machine to 100 ℃, and setting the decocting time to 2 h; switching on a power supply, and starting decoction;
3) after the medicine is decocted, the power supply is cut off; taking out the residue, filtering the medicinal liquid, packaging, and storing at 4 deg.C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910091633.0A CN109620911B (en) | 2019-01-30 | 2019-01-30 | Traditional Chinese medicine composition capable of improving neutropenia after chemotherapy and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910091633.0A CN109620911B (en) | 2019-01-30 | 2019-01-30 | Traditional Chinese medicine composition capable of improving neutropenia after chemotherapy and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109620911A CN109620911A (en) | 2019-04-16 |
| CN109620911B true CN109620911B (en) | 2021-08-31 |
Family
ID=66062859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910091633.0A Active CN109620911B (en) | 2019-01-30 | 2019-01-30 | Traditional Chinese medicine composition capable of improving neutropenia after chemotherapy and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109620911B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1168805A (en) * | 1997-06-20 | 1997-12-31 | 山东东阿阿胶股份有限公司 | Medicine for enriching the blood |
| CN103417724A (en) * | 2012-05-22 | 2013-12-04 | 石家庄以岭药业股份有限公司 | Applications of traditional Chinese medicine composition in preparing medicines capable of improving bodily functions of athlete |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1230160C (en) * | 2003-05-25 | 2005-12-07 | 杭州浙大力夫生物科技有限公司 | Application of bamboo leaf total flavone in medicine for treating and preventing prostata disease and health-care-food |
-
2019
- 2019-01-30 CN CN201910091633.0A patent/CN109620911B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1168805A (en) * | 1997-06-20 | 1997-12-31 | 山东东阿阿胶股份有限公司 | Medicine for enriching the blood |
| CN103417724A (en) * | 2012-05-22 | 2013-12-04 | 石家庄以岭药业股份有限公司 | Applications of traditional Chinese medicine composition in preparing medicines capable of improving bodily functions of athlete |
Non-Patent Citations (1)
| Title |
|---|
| "人参总皂苷胶囊治疗中性粒细胞减少症的临床观察";周郁鸿等;《中国中西医结合杂志》;20001231;539-540 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109620911A (en) | 2019-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110934924A (en) | Traditional Chinese medicine bone marrow hematogenesis composition and application thereof | |
| CN109620911B (en) | Traditional Chinese medicine composition capable of improving neutropenia after chemotherapy and application thereof | |
| CN107854565B (en) | Anti-radiation traditional Chinese medicine composition | |
| CN101843876A (en) | Chinese medicinal composition for preventing renal cell apoptosis and anemia caused by cis-platinum (DDP) and preparation method thereof | |
| CN101474388B (en) | Improved prescription of Xianchan tablet medicament and preparation method thereof | |
| CN101129615A (en) | Caulis spatholobi oral liquid | |
| CN1056752C (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN105456887A (en) | Pharmaceutical for treating aplastic anemia | |
| CN110934974A (en) | Traditional Chinese medicine composition for treating lung cancer, traditional Chinese medicine preparation and preparation method thereof | |
| CN113144019B (en) | A Chinese medicinal composition for treating leukopenia caused by cancer chemotherapy, and its preparation method | |
| CN103191267A (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN1061887C (en) | Shengxuebao-medicine for improving hematopoitic function | |
| CN114224936B (en) | Extraction and purification process of effective part of white ginseng prescription for increasing leucocyte | |
| CN107753638B (en) | Medicine for promoting bone marrow hematopoiesis and preparation method and application thereof | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN114588214B (en) | Composition and granules for improving bone marrow suppression after chemotherapy and preparation method | |
| CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
| CN101020026A (en) | Honeyed Guiqi ointment for enhancing body's resistance and its prepn | |
| CN105687715B (en) | Traditional Chinese medicine composition for treating chronic benzene poisoning thrombopenia and leukopenia | |
| CN1316989C (en) | Capsule with dried human placemta and red sage root and its preparing process | |
| CN106728687B (en) | Traditional Chinese medicine composition for bronchial asthma in remission stage and preparation method thereof | |
| CN105616961A (en) | Cancer chemoradiotherapy adjuvant-therapy traditional Chinese medicine and preparation method thereof | |
| CN118593630A (en) | Traditional Chinese medicine formula suitable for increasing platelets in tumor chemotherapy and preparation method thereof | |
| CN117100800A (en) | Traditional Chinese medicine composition for treating stage 3 and stage 4 pressure sores and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |